FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978103379> ?p ?o ?g. }

• W1978103379 endingPage "2204" @default.
• W1978103379 startingPage "2196" @default.
• W1978103379 abstract "To evaluate the efficacy and safety of interleukin-1 receptor antagonist (IL-1Ra) in patients with rheumatoid arthritis (RA).Patients with active and severe RA (disease duration <8 years) were recruited into a 24-week, double-blind, randomized, placebo-controlled, multicenter study. Doses of nonsteroidal antiinflammatory drugs and/or oral corticosteroids (< or =10 mg prednisolone daily) remained constant throughout the study. Any disease-modifying antirheumatic drugs that were being administered were discontinued at least 6 weeks prior to enrollment. Patients were randomized to 1 of 4 treatment groups: placebo or a single, self-administered subcutaneous injection of IL-1Ra at a daily dose of 30 mg, 75 mg, or 150 mg.A total of 472 patients were recruited. At enrollment, the mean age, sex ratio, disease duration, and percentage of patients with rheumatoid factor and erosions were similar in the 4 treatment groups. The clinical parameters of disease activity were similar in each treatment group and were consistent with active and severe RA. At 24 weeks, of the patients who received 150 mg/day IL-1Ra, 43% met the American College of Rheumatology criteria for response (the primary efficacy measure), 44% met the Paulus criteria, and statistically significant improvements were seen in the number of swollen joints, number of tender joints, investigator's assessment of disease activity, patient's assessment of disease activity, pain score on a visual analog scale, duration of morning stiffness, Health Assessment Questionnaire score, C-reactive protein level, and erythrocyte sedimentation rate. In addition, the rate of radiologic progression in the patients receiving IL-1Ra was significantly less than in the placebo group at 24 weeks, as evidenced by the Larsen score and the erosive joint count. IL-1Ra was well tolerated and no serious adverse events were observed. An injection-site reaction was the most frequently observed adverse event, and this resulted in a 5% rate of withdrawal from the study among those receiving IL-1Ra at 150 mg/day.This study confirmed both the efficacy and the safety of IL-1Ra in a large cohort of patients with active and severe RA. IL-1Ra is the first biologic agent to demonstrate a beneficial effect on the rate of joint erosion." @default.
• W1978103379 created "2016-06-24" @default.
• W1978103379 creator A5001588361 @default.
• W1978103379 creator A5004363203 @default.
• W1978103379 creator A5015121992 @default.
• W1978103379 creator A5022630337 @default.
• W1978103379 creator A5026797171 @default.
• W1978103379 creator A5028429978 @default.
• W1978103379 creator A5037573724 @default.
• W1978103379 creator A5046329367 @default.
• W1978103379 creator A5050714925 @default.
• W1978103379 creator A5058427951 @default.
• W1978103379 creator A5060681737 @default.
• W1978103379 creator A5062493065 @default.
• W1978103379 creator A5068487815 @default.
• W1978103379 creator A5071541433 @default.
• W1978103379 creator A5089477356 @default.
• W1978103379 date "1998-12-01" @default.
• W1978103379 modified "2023-10-10" @default.
• W1978103379 title "Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist" @default.
• W1978103379 cites W1490165777 @default.
• W1978103379 cites W1515994079 @default.
• W1978103379 cites W1520223434 @default.
• W1978103379 cites W1558053349 @default.
• W1978103379 cites W1886972027 @default.
• W1978103379 cites W1948682743 @default.
• W1978103379 cites W1980978904 @default.
• W1978103379 cites W1985004174 @default.
• W1978103379 cites W1990251286 @default.
• W1978103379 cites W1990347684 @default.
• W1978103379 cites W1998253405 @default.
• W1978103379 cites W2014401459 @default.
• W1978103379 cites W2022586945 @default.
• W1978103379 cites W2024171962 @default.
• W1978103379 cites W2026507759 @default.
• W1978103379 cites W2030018500 @default.
• W1978103379 cites W2030353584 @default.
• W1978103379 cites W2031670584 @default.
• W1978103379 cites W2032026472 @default.
• W1978103379 cites W2033299724 @default.
• W1978103379 cites W2041005913 @default.
• W1978103379 cites W2041609594 @default.
• W1978103379 cites W2042417059 @default.
• W1978103379 cites W2043287930 @default.
• W1978103379 cites W2045509256 @default.
• W1978103379 cites W2048462515 @default.
• W1978103379 cites W2064604818 @default.
• W1978103379 cites W2073598149 @default.
• W1978103379 cites W2088158803 @default.
• W1978103379 cites W2092951400 @default.
• W1978103379 cites W2093969242 @default.
• W1978103379 cites W2096491169 @default.
• W1978103379 cites W2121801199 @default.
• W1978103379 cites W2128938421 @default.
• W1978103379 cites W2129195110 @default.
• W1978103379 cites W2133692536 @default.
• W1978103379 cites W2137468010 @default.
• W1978103379 cites W2139162201 @default.
• W1978103379 cites W2142180500 @default.
• W1978103379 cites W2151623627 @default.
• W1978103379 cites W2152348310 @default.
• W1978103379 cites W2167031471 @default.
• W1978103379 cites W2206746226 @default.
• W1978103379 cites W2328587823 @default.
• W1978103379 cites W2332739634 @default.
• W1978103379 cites W4322703114 @default.
• W1978103379 doi "https://doi.org/10.1002/1529-0131(199812)41:12<2196::aid-art15>3.0.co;2-2" @default.
• W1978103379 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9870876" @default.
• W1978103379 hasPublicationYear "1998" @default.
• W1978103379 type Work @default.
• W1978103379 sameAs 1978103379 @default.
• W1978103379 citedByCount "902" @default.
• W1978103379 countsByYear W19781033792012 @default.
• W1978103379 countsByYear W19781033792013 @default.
• W1978103379 countsByYear W19781033792014 @default.
• W1978103379 countsByYear W19781033792015 @default.
• W1978103379 countsByYear W19781033792016 @default.
• W1978103379 countsByYear W19781033792017 @default.
• W1978103379 countsByYear W19781033792018 @default.
• W1978103379 countsByYear W19781033792019 @default.
• W1978103379 countsByYear W19781033792020 @default.
• W1978103379 countsByYear W19781033792021 @default.
• W1978103379 countsByYear W19781033792022 @default.
• W1978103379 countsByYear W19781033792023 @default.
• W1978103379 crossrefType "journal-article" @default.
• W1978103379 hasAuthorship W1978103379A5001588361 @default.
• W1978103379 hasAuthorship W1978103379A5004363203 @default.
• W1978103379 hasAuthorship W1978103379A5015121992 @default.
• W1978103379 hasAuthorship W1978103379A5022630337 @default.
• W1978103379 hasAuthorship W1978103379A5026797171 @default.
• W1978103379 hasAuthorship W1978103379A5028429978 @default.
• W1978103379 hasAuthorship W1978103379A5037573724 @default.
• W1978103379 hasAuthorship W1978103379A5046329367 @default.
• W1978103379 hasAuthorship W1978103379A5050714925 @default.
• W1978103379 hasAuthorship W1978103379A5058427951 @default.
• W1978103379 hasAuthorship W1978103379A5060681737 @default.
• W1978103379 hasAuthorship W1978103379A5062493065 @default.
• W1978103379 hasAuthorship W1978103379A5068487815 @default.

• next